The University of Texas MD Anderson Cancer Center has established a strategic partnership with AstraZeneca focused on ovarian and other gynecologic cancers. MD Anderson and AstraZeneca are going to conduct multiple, parallel clinical and clinically related studies with the goal of improving treatment results in oncology patients.
The collaboration is an unparalleled approach, as the two partners will be dedicated to both clinical trials on investigational treatments, and epidemiological and outcome studies. In addition to enhancing therapeutic outcomes, AstraZeneca and MD Anderson believe they can alter the way in which the industry and the academia approach research and collaborative work, as they want to deepen partnerships and accelerate the development of treatments for women with high unmet medical needs.
“Ovarian and other gynecologic cancers remain areas of high unmet need,” said the chair of Systems Biology of the Division of Cancer Medicine at MD Anderson, Gordon Mills, M.D., Ph.D. The investigator is also the co-leader of MD Anderson’s Breast and Ovarian Cancer Moon Shot, a program focused on accelerating the transition of scientific discoveries into clinical advances and decrease the deaths by cancer, in which the collaboration will be based.
“Collaborations that examine new agents and explore disease epidemiology and outcomes have the potential to inform the development of novel and combination treatments, and MD Anderson has the ability and expertise required to provide data-rich, rapid trials to inform this combination strategy,” added Mills.
“AstraZeneca is committed to helping redefine the cancer treatment paradigm, beginning with our powerful clinical development program for ovarian cancer,” stated the chief medical officer U.S., AstraZeneca, Greg Keenan. “Working to fully realize the potential of novel targeted therapies and immunotherapies, as well as novel combinations to drive improved outcomes, engages us in true partnerships to better understand the science. The collaboration with MD Anderson is ideal as it maximizes both our ability to explore these combinations through AstraZeneca’s robust pipeline while providing us with unique insights and data.”
The research will also include assistance from MD Anderson’s Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT), which is co-directed by Gordon Mills. In addition, AstraZeneca is planning on provide six new cancer medicines to the oncology market until 2020, as the company has been focused on treating breast, ovarian, lung and hematological cancers through their key platforms of immunotherapy, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates (ADCs).